Since AP-1 signaling drives SMOi resistance through MRTF activation, we predicted that in treatment of patient tumors, AP-1 inhibitors, like MRTF inhibitors12, would only display efficacy in BCC populations with nMRTF. This evidence concerns the gene JUNB and skin basal cell carcinoma.